Sign In
Last checked at 
15 Jan 2018 10:58
Hardman Research: Affimer Drug Conjugates a reality
Affimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. In addition, Avacta is using external collaborations to expand the opportunities for its Affimer technology. A proof-of-concept study combining its Affimer technology with Glythera's Permalink chemistry to generate Affimer Drug Conjugates has concluded successfully.
Please click here for the full report:
http://www.hardmanandco.com/docs/default-source/company-docs/avacta-documents/15.01.18-affimer-drug-conjugates-a-reality.pdf
To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH Follow us on Twitter @HardmanandCo | Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave
+44 20 7194 7622 |
mh@hardmanandco.com dmh@hardmanandco.com gp@hardmanandco.com
www.hardmanandco.com |
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Follow the stocks
